Phase I Study of EOC202 Plus Paclitaxel in Chinese Patients With Metastatic Breast Cancer

NCT03600090 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor, Adult

Interventions

BIOLOGICAL: EOC202
DRUG: Paclitaxel

Sponsor

Taizhou EOC Pharma Co., Ltd.